- * • Adults aged greater than or equal to (\>=) 18 years on the day of signing the informed consent form.
- * • Confirmed diagnosis of SCD of any genotype.
- * • Experienced 1 to 12 VOCs requiring a visit to a medical facility and treatment with parenteral opioids or a parenteral nonsteroidal anti-inflammatory drug within the 12 months before Screening.
- * • HU Regimen:
- * a. On stable and well-tolerated Hydroxyurea (HU) regimen for at least 30 days before Screening.
- * or
- * b. HU was discontinued or refused (eg, due to concern of side effects or lack of effect).
Sickle Cell Disease
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
NCT07224360 | PHASE 2 | INTERVENTIONAL
This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.
Trial Information
If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
UAMS Medical Center
Little Rock,Arkansas,United States,72202
The Foundation for Sickle Cell Disease
Hollywood,Florida,United States,33023
Center for Cancer and Blood Disorders
Bethesda,Maryland,United States,20817
Southern Specialty Research
Flowood,Mississippi,United States,39232
Jacobi Medical Center
The Bronx,New York,United States,10461
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov